(NASDAQ: JANX) Janux Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Janux Therapeutics's earnings in 2026 is -$99,849,000.On average, 20 Wall Street analysts forecast JANX's earnings for 2026 to be -$109,842,589, with the lowest JANX earnings forecast at -$137,307,824, and the highest JANX earnings forecast at -$65,013,499. On average, 19 Wall Street analysts forecast JANX's earnings for 2027 to be -$166,076,267, with the lowest JANX earnings forecast at -$205,062,340, and the highest JANX earnings forecast at -$131,697,305.
In 2028, JANX is forecast to generate -$196,270,283 in earnings, with the lowest earnings forecast at -$305,195,121 and the highest earnings forecast at -$44,327,386.